Helix BioMedix scientists have created a vast library of proprietary peptides initially based upon the diversity of structures, functions and activities of innate immunity peptides. From this library specific activities have been identified, isolated and characterized resulting in short bioactive peptides exhibiting antimicrobial, anti-inflammatory, anti-glycation, proliferative or wound healing properties. The development of peptide analogs for human use has been hampered in the past for a number of reasons. Many peptides and proteins are multifunctional and thus exhibit unwanted activities together with those that are desired. They are often large, creating problems related to ease of administration and cost. In the development of Helix BioMedix peptides well-defined criteria have been employed to create small bioactive peptides exhibiting specific activities in the minimum number of amino acids.
Expanding beyond innate immunity the same rationale has been used to develop sequences that mimic signals produced by the body to elicit dermal repair for example through extracellular matrix synthesis and barrier function restoration and skin protection through melanin synthesis. As a result of this work the Helix bioactive peptide library continues to grow in diversity and size.
As a result, a wide range of commercially viable peptides have been developed.
For any partnership interest, please contact our CEO, Robin L. Carmichael at BusDev@HelixBioMedix.com